Antineoplastics
1
Reactions 1387 - 4 Feb 2012 S Antineoplastics Various toxicities in older patients: 13 case reports Thirteen men with testicular germ cell cancer received antineoplastics including bleomycin, etoposide, cisplatin, cyclophosphamide and carboplatin, and developed various adverse events [see table 1]. Patient characteristics Patient/ Chemotherapy Adverse events (grade a ) age (y) (no. of cycles) 1/60 BEP (4) thrombocytopaenia (4); sensory neuropathy (3) 2/66 EP (4) vomiting (2) 3/61 carboplatin (4) nausea (1) 4/61 CyE (6) vomiting (1) 5/68 BEP (4) febrile neutropaenia (3); hypocalcaemia (2); hypomagnesaemia (2) 6/85 carboplatin (4) nausea (2) 7/63 EP (4) febrile neutropaenia (3) 8/73 BEP (3) febrile neutropaenia (3); vomiting (3); tinnitus (2) 9/60 BEP b (6) thrombocytopaenia (4); anaemia (3) 10/65 EP (3) then EC (1) febrile neutropaenia (4); elevated creatinine (2); deep vein thrombosis (3) 11/64 EP (4) febrile neutropaenia (3); sensory neuropathy (2) 12/71 EP b (4) nausea (2); sensory neuropathy (1) 13/69 BEP (1) then elevated creatinine (2); EP (1) then EC (2) gastrointestinal bleed (3) a CTCAE version 3 b reduced dose Treatments included BEP (bleomycin 30 000IU day 2, cisplatin 100 mg/m 2 , etoposide 500 mg/m 2 ), EP (cisplatin 100 mg/m 2 , etoposide 500 mg/m 2 ), carboplatin (full dose, AUC 5), CyE (oral cyclophosphamide and etoposide), EC (etoposide and carboplatin), and EP (etoposide and cisplatin) [all other routes, dosages and frequencies not stated; treatment durations to onset of reactions and outcomes not stated]. Wheater MJ, et al. The clinical features and management of testicular germ cell tumours in patients aged 60 years and older. BJU International 108: 1794-1799, No. 11, Dec 2011. Available from: URL: http://dx.doi.org/10.1111/ j.1464-410x.2011.10252.x - United Kingdom 803066442 1 Reactions 4 Feb 2012 No. 1387 0114-9954/10/1387-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1387 - 4 Feb 2012
SAntineoplastics
Various toxicities in older patients: 13 casereports
Thirteen men with testicular germ cell cancer receivedantineoplastics including bleomycin, etoposide, cisplatin,cyclophosphamide and carboplatin, and developed variousadverse events [see table 1].
Patient characteristicsPatient/ Chemotherapy Adverse events (gradea)age (y) (no. of cycles)
1/60 BEP (4) thrombocytopaenia (4); sensoryneuropathy (3)
2/66 EP (4) vomiting (2)3/61 carboplatin (4) nausea (1)4/61 CyE (6) vomiting (1)5/68 BEP (4) febrile neutropaenia (3);
hypocalcaemia (2);hypomagnesaemia (2)
6/85 carboplatin (4) nausea (2)7/63 EP (4) febrile neutropaenia (3)8/73 BEP (3) febrile neutropaenia (3);
vomiting (3); tinnitus (2)9/60 BEPb (6) thrombocytopaenia (4);
anaemia (3)10/65 EP (3) then EC (1) febrile neutropaenia (4); elevated
creatinine (2); deep veinthrombosis (3)
11/64 EP (4) febrile neutropaenia (3); sensoryneuropathy (2)
12/71 EPb (4) nausea (2); sensoryneuropathy (1)
13/69 BEP (1) then elevated creatinine (2);EP (1) then EC (2) gastrointestinal bleed (3)
a CTCAE version 3b reduced dose
Treatments included BEP (bleomycin 30 000IU day 2,cisplatin 100 mg/m2, etoposide 500 mg/m2), EP (cisplatin100 mg/m2, etoposide 500 mg/m2), carboplatin (full dose,AUC 5), CyE (oral cyclophosphamide and etoposide), EC(etoposide and carboplatin), and EP (etoposide andcisplatin) [all other routes, dosages and frequencies notstated; treatment durations to onset of reactions andoutcomes not stated].Wheater MJ, et al. The clinical features and management of testicular germ celltumours in patients aged 60 years and older. BJU International 108: 1794-1799,No. 11, Dec 2011. Available from: URL: http://dx.doi.org/10.1111/j.1464-410x.2011.10252.x - United Kingdom 803066442
1
Reactions 4 Feb 2012 No. 13870114-9954/10/1387-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
